What Happens During a Lutetium-177 PSMA Therapy Session: Infusion, Fluids and Monitoring

Ray is 74, and he has arrived forty minutes early with a folder of scan reports and a daughter who has read more about prostate cancer than she ever wanted to. His question for the nurse is not about survival statistics. It is smaller and more practical: how long will I be sitting in that chair, and will I glow?

It is a fair question. Most people can picture chemotherapy or a course of external radiotherapy. A lutetium 177 PSMA treatment session fits neither picture. The medicine arrives in a shielded container, goes in through an ordinary vein, and does its work quietly over the following days. There is no machine humming overhead, and the appointment is often shorter than a busy afternoon at the clinic.

What follows is a walk through that afternoon, from the blood test that decides whether the day goes ahead to the drive home and the few unusual rules that come with it. The details vary between centers, so treat this as a map, not a script; your treating team will fill in the specifics.

What is a lutetium 177 PSMA treatment session?

Strip away the jargon and a lutetium 177 PSMA treatment session is a scheduled outpatient appointment where a radioactive medicine is delivered into a vein. The medicine belongs to a class called radioligand therapy: a targeting molecule (the ligand) carries a radioactive atom (the radionuclide) to cancer cells that display a particular surface protein. Here the target is prostate-specific membrane antigen, or PSMA, a protein found in unusually high amounts on most prostate cancer cells. The radioactive atom is lutetium-177, a metal that gives off short-range radiation as it decays.

The generic name of the approved agent is lutetium Lu 177 vipivotide tetraxetan, and in trials it is often written as 177Lu-PSMA-617. Whatever the label on the vial, the structure of the visit is broadly the same: pre-treatment checks, a period of drinking or intravenous fluids, the infusion itself, a monitoring window, a radiation safety check, and discharge with instructions.

Two features surprise people. First, the infusion is brief. In the pivotal phase 3 study, known as VISION, the medicine was given intravenously at six-week intervals, and the administration itself took minutes rather than hours (PubMed, Sartor et al.). Second, nearly everything else about the day exists to protect healthy tissue, not to fight the cancer. The fluids, the bladder emptying, the distance rules afterwards: all of it is about steering radiation away from kidneys, salivary glands and bystanders.

Because the medicine keeps emitting radiation after it leaves the clinic, the session extends, in a sense, into your home. That is the part that needs the most explaining, and it is where we will spend a good deal of this article.

How does lutetium 177 PSMA work inside the body?

Think of PSMA as a docking port that prostate cancer cells install on their outer surface in far greater numbers than normal cells do. The ligand part of the medicine is shaped to fit that port. Once injected, it circulates in the blood, finds PSMA-rich cells wherever they are, whether in bone, lymph nodes or soft tissue, and locks on. The cell then pulls the whole complex inside.

Now the radioactive passenger matters. Lutetium-177 decays by releasing beta particles, tiny high-energy electrons that travel only a couple of millimeters through tissue. That short range is the point. Energy is deposited into the cancer cell and its immediate neighbors, damaging DNA beyond repair, while cells a little farther away receive very little. It also emits a small amount of gamma radiation, which is what allows a scanner to picture where the medicine has gone and what makes a Geiger counter tick when it is held near you after the infusion.

The medicine that does not bind to cancer cells is cleared mainly by the kidneys into the urine. Salivary glands, tear glands, the small intestine and the kidneys themselves also express some PSMA, which explains the most common side effects: dry mouth, nausea and, for some people, changes in kidney blood tests (National Cancer Institute PDQ; PubMed, Sartor et al.). Bone marrow is exposed when the cancer sits in bone, which is why blood counts are watched so closely.

This mechanism is why a PSMA PET scan comes first. If the cancer does not display enough of the target, the medicine has nowhere to dock, and the treatment would expose healthy organs for little gain. Radioligand therapy is precision medicine in the literal sense: the map decides whether the missile is worth launching.

Who is usually offered lutetium 177 PSMA therapy, and who is asked to wait?

Eligibility rests on three pillars: the stage of the cancer, what has already been tried, and whether the body can safely absorb the treatment.

Regarding stage and prior treatment, the VISION trial enrolled men with metastatic castration-resistant prostate cancer, meaning cancer that had spread and kept growing despite testosterone-lowering treatment, who had already received at least one androgen-receptor pathway inhibitor and one or two taxane-based chemotherapy regimens (PubMed, Sartor et al.). A later trial in men who had not yet had chemotherapy led regulators to permit use earlier in the pathway, so the exact position in a person’s treatment sequence is now a conversation with the oncology team rather than a fixed rule (National Cancer Institute PDQ).

Regarding the target, every candidate needs a PSMA PET scan showing that the tumors take up the tracer strongly. Men whose scans show PSMA-negative disease, or a mix where large deposits lack the target, are generally not offered this therapy because it is unlikely to reach the cancer.

Regarding the body’s reserve, the team looks at:

• Kidney function, since the medicine is cleared in urine and the kidneys receive radiation along the way.
• Bone marrow, reflected in hemoglobin, white cell and platelet counts, which must be adequate before each cycle.
• Liver function and general fitness, including the ability to manage fluids and follow precautions at home.
• Urinary control, because incontinence changes how radiation safety at home is handled, though it is often manageable with planning.

Being asked to wait is common and is not a verdict. Low platelets after recent chemotherapy, a urinary infection, or a temporary dip in kidney function can each postpone a cycle for a week or two. The Mayo Clinic notes that treatment plans for advanced prostate cancer are individualized according to the cancer’s behavior and overall health (Mayo Clinic). The team is choosing the safest moment, not withholding care.

Before the session: the checks that decide whether the day goes ahead

Most centers draw blood a few days before each cycle, and the results are the gatekeeper. Nurses are looking for the same things they checked at eligibility: enough platelets and neutrophils to withstand another hit to the marrow, a hemoglobin level that will not leave you breathless, and kidney numbers that have not drifted. If anything falls outside the center’s thresholds, the session is delayed rather than adjusted on the spot. That decision belongs to the prescribing physician.

You will also be asked about symptoms since the last cycle: mouth dryness, nausea, bone pain, fatigue, bleeding or bruising, and how much you have been drinking. Honest answers matter here more than stoicism. A man who mentions that his urine has been dark for a week is giving the team information they can act on.

Practical preparation is straightforward and usually includes:

• Eating a light meal beforehand, since fasting is not normally required and hunger only makes nausea worse.
• Starting to drink more water from the evening before, unless you have been told to restrict fluids for heart or kidney reasons.
• Bringing a list of current medicines, including over-the-counter and herbal products, for the pharmacist to review.
• Wearing comfortable clothes with a sleeve that rolls up easily.
• Arranging transport, ideally with a driver who can sit at a distance afterwards.

Some centers ask you to take an anti-nausea tablet before arrival; that is a prescribed decision and the timing will come from them. Others give it intravenously on the day. Neither approach is more correct; they reflect local protocols.

If you have a urinary catheter or a stoma, tell the team well in advance. Both are workable, but the radiation safety staff will want to explain how to handle bags and disposal. Plan for the whole visit to occupy the better part of a day, even if the infusion itself is short.

What happens on the day: arrival, cannula and the infusion

The room looks like any infusion suite, apart from a few clues: a lead-lined container on a trolley, a handheld radiation meter on the desk, and staff who stand a little farther back than you might expect. You will be checked in, your identity confirmed against the prescription, and a small cannula placed in a vein in the arm or hand. A good vein matters. If the medicine leaks into the tissue around the vein, it can cause local irritation, so nurses are careful about placement and will flush the line with saline to confirm it runs freely.

Anti-nausea medicine, if it is part of your plan, usually goes in first. Then comes the wait for the radiopharmacy to confirm the activity in the vial, which is measured for each person individually. A physician or nuclear medicine technologist administers the medicine, often over a few minutes, either as a slow push from a shielded syringe or as a short drip from a small bag. Some centers use a pump; some let gravity do the work. You will feel the coolness of saline, and that is generally all.

People are often struck by how ordinary it feels. There is no heat, no taste, no rush of sensation. The ligand is silently seeking out PSMA while you read a magazine. After the medicine is in, the line is flushed again so that none of it remains in the tubing.

The cannula usually stays in for a while, partly so intravenous fluids can continue and partly so that treatment for an allergic reaction could be given quickly if one occurred. Serious hypersensitivity reactions are uncommon, but the preparation is standard for any intravenous medicine (National Cancer Institute PDQ).

From this point on, the clock that matters is not the infusion clock but the radiation clock. Every hour that passes, and every trip to the bathroom, lowers the amount of radioactivity you carry.

Fluids and monitoring: what the nurses are watching and why

If the infusion is the shortest part of a lutetium 177 PSMA treatment session, the fluids are the longest. Unbound medicine leaves the body through the kidneys, so the aim is to dilute it and move it out quickly, reducing the time radiation spends in the kidney tissue and the bladder wall. Nurses will hand you water, or run saline through the cannula, or both, and they will ask you to empty your bladder often. In the hours after treatment, your urine is where most of the excreted radioactivity ends up, which is why the bathroom you use may be a designated one.

Monitoring is calm rather than dramatic. Expect:

• Blood pressure, pulse and temperature before the infusion and at intervals afterwards.
• Questions about nausea, flushing, itching or breathing changes, which could suggest a reaction.
• A check of the cannula site for pain or swelling that might indicate leakage.
• A radiation survey, in which a meter is held at set distances from your body to estimate how much radioactivity you still carry and to tailor your home instructions.

Some centers perform a scan on the same day or the next, using the gamma emissions from lutetium-177 to picture where the medicine has settled. This post-treatment image is not a progress report on the cancer; it is a quality check confirming the medicine went where the PSMA PET predicted.

The length of the observation window varies between centers and depends on national regulations and the reading on the radiation meter. Most people are discharged the same day once staff are satisfied that you are well, that you can drink and pass urine normally, and that the measured radiation falls under the local release threshold. A small number, for example those with limited mobility or difficulty following precautions, may be kept overnight in a shielded room. That is a safety arrangement, not a sign that anything has gone wrong.

Lutetium 177 PSMA treatment session at a glance

People remember a day better when they can see its shape. The table below sets out the typical sequence of a treatment visit and what each step is for. Timings are approximate and differ between centers; use it to orient yourself, not to hold anyone to a schedule.

Step	What happens	Why it matters
Pre-treatment blood tests	Blood counts, kidney and liver tests drawn a few days before	Decides whether the cycle proceeds or is delayed
Check-in and consent	Identity confirmed, symptoms reviewed, questions answered	Ensures the right person, right medicine, right day
Cannula and pre-medication	Intravenous line placed; anti-nausea medicine if prescribed	Secure access reduces leak risk; nausea is a common side effect
Fluids begin	Water by mouth and/or intravenous saline	Speeds clearance through kidneys, protects bladder
Infusion	Medicine given over a few minutes from a shielded syringe or bag	Delivers the radioligand into the bloodstream
Observation	Vital signs, symptom checks, frequent bladder emptying	Detects reactions early; lowers radiation retained
Radiation survey	Meter readings at set distances	Confirms safe release and shapes home precautions
Optional imaging	Gamma scan same day or next	Confirms medicine reached PSMA-positive sites
Discharge	Written precautions, contact numbers, next appointment	Extends safety into the home for the first days

In the VISION trial, cycles were repeated at six-week intervals for up to six cycles (PubMed, Sartor et al.), so most people will walk through this table several times. The steps rarely change, but your familiarity with them will, and by the third visit many people describe the routine as oddly reassuring.

Lutetium 177 therapy precautions: going home the same day

Here is where a lutetium 177 PSMA treatment session differs from every other cancer therapy you may have had. You leave carrying a small amount of radioactivity, most of which is excreted in urine over the first day or two, and the rest of which decays over roughly a week as lutetium-177 loses half its activity every six to seven days. The precautions are designed around those two facts.

Written instructions from the radiation safety team typically cover:

• Fluids: keep drinking and keep emptying your bladder, since the fastest route out of the body is the toilet.
• Toilet hygiene: sit to urinate to avoid splashing, flush twice with the lid down, and wash hands thoroughly. Small spills should be wiped with disposable tissue and flushed.
• Distance: keep a comfortable arm’s length or more from others where practical, and avoid prolonged close contact for the number of days your team specifies.
• Sleeping arrangements: many centers advise sleeping in a separate bed for a short period, especially if the partner is pregnant.
• Children and pregnancy: limit close contact with young children and pregnant women for the period stated, because developing tissue is more radiation-sensitive.
• Laundry and dishes: normal washing is usually sufficient; underwear and bedding soiled with urine may need a separate wash.
• Travel: carry the card the center gives you, since sensitive detectors at borders or airports can pick up residual radiation for weeks.

The exact number of days is set by the reading on the radiation meter at discharge and by national regulations, which is why we are not printing a single figure here. Two men treated on the same afternoon may receive different instructions, and both will be right for them.

One misconception deserves an early correction: the radiation does not make your skin, sweat or breath dangerous in the way people imagine from films. Urine is the main issue. Sensible hygiene and a little distance are the whole of it, and the rules relax quickly.

Lutetium PSMA treatment cycles: how many and how far apart?

A single session almost never stands alone. The published evidence, and the labeling that grew out of it, describe a course of repeated cycles with rest periods between them. In the VISION trial, the medicine was given every six weeks for four cycles, with the option of extending to a total of six cycles in men who were tolerating treatment and appeared to be benefiting (PubMed, Sartor et al.).

Why six weeks? The interval gives bone marrow time to recover from the small radiation exposure it receives, lets kidney function be rechecked, and allows the lutetium-177 from the previous cycle to decay away almost completely before the next arrives. It also gives the team a chance to look at the PSA blood test and, when needed, imaging, to judge whether the treatment is doing what was hoped.

Not everyone completes the full course, and this happens for several reasons:

• Blood counts, particularly platelets, fall too low and do not recover in time.
• Kidney tests worsen beyond an acceptable threshold.
• Scans or PSA show the cancer progressing despite treatment, prompting a change of strategy.
• Side effects such as fatigue or dry mouth become hard to live with.
• Occasionally, a very good response leads a team to pause early and hold remaining cycles in reserve.

Each of these is a clinical judgment made by the treating oncologist and nuclear medicine physician together, and none should be pre-empted at home. Stopping, delaying or resuming is always their call, informed by your priorities.

Timing questions often arise around other treatments. Hormone therapy generally continues throughout. Chemotherapy, bone-strengthening agents and radiotherapy to painful bone sites each require coordination, since all can affect marrow or overlap in side effects. The National Cancer Institute’s treatment summary lists radioligand therapy among the options for castration-resistant disease alongside these other approaches (National Cancer Institute PDQ), which is a reminder that sequencing, not any single drug, is the real art of managing advanced prostate cancer.

PSMA lutetium side effects: what the evidence actually shows

The honest picture is that most side effects are mild to moderate and predictable from the mechanism, with a smaller number that need monitoring by blood test rather than by how you feel.

The most frequently reported effects in the VISION trial were fatigue, dry mouth, nausea, anemia, decreased appetite and constipation (PubMed, Sartor et al.). Each maps onto a tissue that either expresses PSMA or lies in the path of excretion:

• Dry mouth arises because salivary glands carry some PSMA and take up the medicine. It is usually mild and often improves between cycles, though it can persist. Sipping water, sugar-free gum and good dental care help; the team may suggest other measures.
• Nausea tends to peak in the first day or two and responds to standard anti-nausea approaches prescribed by the team.
• Fatigue is common to nearly all cancer treatments and tends to accumulate over the course rather than appear all at once (NHS radiotherapy guidance).
• Low blood counts, including anemia, low platelets and low white cells, occur because the marrow, especially in men with extensive bone disease, receives radiation. These are found on blood tests and may cause breathlessness, bruising or infection risk when marked.
• Kidney effects are watched through blood tests over the whole course and beyond, since radiation injury to the kidney can develop slowly.

Serious adverse events were more common in the treatment arm than in the standard-care arm in VISION, though most were manageable, and the trial’s authors judged the overall balance favorable for the population studied (PubMed, Sartor et al.). That is a description of a trial population, not a prediction for you.

Two effects people worry about rarely happen: hair loss is not expected, and there is no pattern of nerve damage in the hands and feet, which is a relief to men who have been through taxane chemotherapy. A dry or gritty eye occasionally occurs because tear glands carry PSMA too. Report anything new; the team would rather hear about a minor symptom than miss an early signal.

What the days and weeks after a session usually look like

The first two days are about fluids and hygiene. Many people feel largely normal, perhaps a little tired, perhaps slightly queasy. Nausea, if it comes, tends to arrive within the first day and settle within a few. The precautions on your written sheet are most important in this window because urine carries the bulk of the excreted radioactivity early on.

By the end of the first week, most home restrictions have relaxed or ended, according to the timeline your center gave you. Dry mouth may become noticeable around now, and fatigue, if it is going to appear, often shows itself as a mid-afternoon flatness rather than exhaustion. Gentle activity helps rather than hinders; the NHS advises people receiving radiation-based treatment to stay as active as they comfortably can (NHS radiotherapy guidance).

Weeks two to four are the quiet stretch. Blood counts are typically at their lowest somewhere in this period, which is why the team may schedule a blood test even if you have no appointment. Watch for unusual bruising, bleeding gums or a fever, and know whom to call. PSA is often checked before the next cycle rather than immediately after this one, because a single early reading can be misleading.

Around week five, pre-cycle blood tests are repeated and the decision about the next session is made. If counts have recovered and kidney function is stable, the cycle proceeds on schedule; if not, it is pushed back.

After the final cycle, follow-up continues for months. Kidney and blood tests are repeated at intervals because radiation effects on these organs can be delayed, and imaging is arranged according to the team’s judgment. The Mayo Clinic describes ongoing monitoring as a standard part of managing advanced prostate cancer regardless of the treatment used (Mayo Clinic). Think of the course as a chapter with a long epilogue rather than a story that ends at the last infusion.

What people often get wrong about lutetium PSMA therapy

Because radioligand therapy is newer than chemotherapy and hormone treatment, it has attracted a cloud of half-truths. A few deserve direct correction.

“It is a last resort.” It was first studied in men who had exhausted hormonal agents and chemotherapy (PubMed, Sartor et al.), and that history colors how people speak of it. Later evidence supported use before chemotherapy in some situations (National Cancer Institute PDQ). Where it sits in your pathway depends on your cancer’s biology and your team’s judgment, not on a fixed ranking.

“One session will show whether it works.” PSA can fluctuate, and imaging changes lag behind biology. Teams generally judge response over two or more cycles, and a modest early change in either direction is not a verdict.

“I will be radioactive for months and dangerous to my family.” Lutetium-177 loses half its activity roughly every week, and most of the unbound medicine leaves in urine within days. Precautions are measured in days, and they concern urine hygiene and close contact, not casual presence in the same room.

“It replaces hormone therapy.” Androgen deprivation almost always continues alongside it. Stopping any prescribed medicine is a decision for the prescribing clinician.

“Everyone with prostate cancer can have it.” It is intended for metastatic disease that has become resistant to hormone treatment and that shows strong PSMA uptake on a PET scan. Men with localized cancer, or with PSMA-negative disease, are not candidates.

“Radiation means hair loss and terrible sickness.” Hair loss is not expected, and nausea is usually manageable with the medicines the team prescribes.

“A PSMA scan and PSMA therapy are the same thing.” The scan uses a tiny tracer amount for imaging; the therapy uses a far larger therapeutic amount. The scan tells the team whether the therapy could reach the cancer. Confusing the two leads to mistaken fears about the diagnostic scan, which carries only the small exposure of any PET study.

Questions to ask your care team before your first session

A first lutetium 177 PSMA treatment session goes more smoothly when the unknowns have been named out loud. Write these down and bring them; many centers assign a specialist nurse whose role includes exactly this conversation.

• What did my PSMA PET scan show, and how strongly did the tumors take up the tracer compared with normal tissue?
• Where does this treatment sit in my overall plan, and what would we consider if it does not help or if it has to stop early?
• How many cycles are you planning, and what would make you delay or stop one?
• Which blood tests will you follow, and how will I be told the results?
• Will I be able to go home the same day, and what specific precautions apply to my household, including children, grandchildren or a pregnant relative?
• How should I manage my urine at home, and what should I do about a spill or an accident?
• Which of my current medicines should I keep taking on treatment day, and are there any you want to review before I start?
• What will you give me for nausea, and when should I take it?
• How will we know whether the treatment is working, and when will you first look?
• What symptoms should prompt me to call, and which number do I ring outside office hours?
• Can I keep driving, working, exercising and being intimate with my partner, and are there timing rules for any of these?
• If I have bone pain, how will you manage it during the course, and can I still have radiotherapy to a painful spot?
• Will I need a scan after the infusion, and what does that scan tell you?
• Who coordinates between the oncology team and the nuclear medicine team, and who is my main point of contact?

Ask, too, about the practicalities that are easy to forget: parking for a driver who needs to wait at a distance, whether a companion can sit with you during the infusion, and what happens if you feel unwell on the way home. Small answers reduce big worries.

When to call your doctor

Most of the effects of a lutetium 177 PSMA treatment session are mild and expected. A small number of symptoms need a same-day phone call, and a few need emergency care. Your team will give you a contact number; keep it on the fridge and in your phone.

Seek urgent or emergency care if you develop:

• A fever, shaking chills or feeling suddenly very unwell, which can signal infection when white cells are low.
• Bleeding that will not stop, blood in urine or stool, or widespread unexplained bruising, which may indicate low platelets.
• Chest pain, severe breathlessness, or a swollen, painful calf, which could reflect anemia, a clot or a heart problem.
• Difficulty breathing, facial swelling or a spreading rash in the hours after the infusion, suggesting an allergic reaction.
• Confusion, fainting or a seizure.

Call the team the same day if you notice:

• Vomiting that prevents you keeping fluids down for more than a day, since dehydration stresses the kidneys.
• Passing much less urine than usual, or none, or urine that is very dark despite drinking.
• Pain, redness or swelling at the cannula site that is getting worse rather than better.
• New or rapidly worsening bone pain, or weakness or numbness in the legs, which can be signs of pressure on the spinal cord and always warrant prompt assessment.
• Persistent diarrhea, severe mouth dryness that stops you eating, or unusual sleepiness.

Mention any of these even if they seem minor. Teams would rather see you once unnecessarily than miss the start of a problem. Between appointments, general fatigue, mild nausea and a dry mouth are usually managed by phone advice and the medicines already prescribed.

Every decision about continuing, pausing or changing treatment rests with your treating oncologist and nuclear medicine physician, who know your scans, your blood results and your goals. This article can describe the path; only they can walk it with you.

Frequently asked questions

What is the life expectancy of patients treated with 177Lu-PSMA?

No one can give an individual life expectancy; it depends on how widespread the cancer is, how it has responded to earlier treatments, and overall health. In the VISION phase 3 trial, men receiving lutetium-177 PSMA plus standard care lived longer on average than those receiving standard care alone, with the difference measured in months, and the treatment also delayed cancer progression. Your oncologist can interpret what that evidence means for your situation.

Is a PSMA scan painful?

No. A PSMA PET scan involves a small injection of a tracer into a vein, a wait of about an hour while it distributes, and then lying still on a scanner table for a period. The needle is the only discomfort. The tracer amount is tiny compared with the therapeutic medicine and carries only the low radiation exposure of any PET study. People with back pain sometimes find lying flat the hardest part; tell staff in advance.

What are the newest treatments for advanced prostate cancer?

Recent additions include radioligand therapy such as lutetium-177 PSMA, PARP inhibitors for cancers with certain DNA-repair gene changes, newer androgen-receptor pathway inhibitors used earlier in the disease, and PSMA PET imaging that detects spread more precisely. Combinations and sequencing are the focus of ongoing trials. Which options apply to you depends on cancer genetics, prior treatment and fitness, and should be discussed with your treating team rather than chosen from a list.

What percentage of prostate cancer patients are PSMA positive?

Most men with advanced prostate cancer show PSMA uptake on a PET scan; in the VISION trial screening process, the large majority of men scanned were eligible on that basis. A minority have low or absent PSMA expression, sometimes in aggressive or neuroendocrine-type tumors, and they are generally not candidates for this therapy. The only way to know your status is the scan itself, which your team will arrange before considering treatment.

How does lutetium 177 PSMA work?

The medicine pairs a molecule shaped to bind prostate-specific membrane antigen, a protein abundant on most prostate cancer cells, with the radioactive metal lutetium-177. After injection it circulates, attaches to PSMA-rich cells anywhere in the body, and is drawn inside. Lutetium-177 then emits short-range beta particles that damage the cancer cell’s DNA. Medicine that does not bind is cleared mainly through the kidneys into urine over the following days.

How many lutetium PSMA treatment cycles will I need?

In the VISION trial, treatment was given every six weeks for four cycles, extendable to six in men tolerating it and appearing to benefit. Your actual number depends on blood counts, kidney function, side effects and how the cancer responds, all reviewed before each cycle. Some men stop early, either because of side effects or because the team judges that further cycles are not needed at that point. The decision rests with your treating physicians.

What are the most common PSMA lutetium side effects?

Fatigue, dry mouth, nausea, anemia, reduced appetite and constipation were the most frequently reported effects in the VISION trial. Low platelets and white cells can also occur, found on blood tests rather than felt. Kidney function is monitored throughout because the medicine is cleared through the kidneys. Hair loss and nerve damage in the hands and feet are not expected. Most effects are mild to moderate and managed with medicines your team prescribes.

Can I be around my family after a lutetium 177 PSMA treatment session?

Yes, with short-term adjustments. The main sources of exposure to others are urine and prolonged close contact, so centers advise careful toilet hygiene, sleeping separately for a short period, and limiting extended close contact with young children and pregnant women for a number of days set by your discharge radiation reading. Sharing a room, preparing food and ordinary conversation are generally fine. Follow the written sheet your center gives you.

Do I have to stay in hospital overnight after lutetium PSMA therapy?

Most people go home the same day once staff confirm they are well, can drink and pass urine, and the radiation meter reading falls below the local release threshold. Some centers, or some countries’ regulations, require a short stay in a shielded room, and people who cannot manage precautions at home may be kept overnight. Which applies to you depends on where you are treated and on your circumstances.

What should I do if I feel sick after the infusion?

Take the anti-nausea medicine your team prescribed, as they directed, and keep sipping fluids, because staying hydrated protects your kidneys and helps clear the medicine. Nausea usually peaks in the first day or two and settles. If you cannot keep fluids down for more than a day, are passing very little urine, or develop fever, contact your team the same day. Do not adjust or add medicines without checking with them.

References

• Prostate cancer: Treatment: NHS
• Radiotherapy: Side effects: NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.